3 research outputs found
Single nucleotide polymorphisms in the Anti-Mullerian hormone (AMH Ile(49)Ser) and Anti-Mullerian hormone type II receptor (AMHRII-482 A > G) as genetic markers in assisted reproduction technology
The aim of the study was to evaluate whether the presence Antimullerian
hormone (AMH) and Antimullerian hormone type II receptor (AMHRII) single
nucleotide polymorphisms (SNPs) Ile(49)Ser and -482A > G respectively
are related to the assisted reproduction outcome.
A prospective cross-sectional observational study was conducted in order
to assess the distribution of AMH and AMHRII SNPs in two cohorts, one of
healthy women (N = 100) and the control group and the IVF/ICSI group (N
= 151) consisted of women undergoing IVF/ICSI treatment for infertility.
Furthermore, a prospective longitudinal observational study was
performed on the latter group to assess possible associations of these
SNPs with patients’ characteristics and controlled ovarian stimulation
(COS) and pregnancy outcome.
Among non-carriers of the AMH (Ile(49)Ser) polymorphism, basal FSH
levels were lower in those with more than two of previous IVF attempts
and fertilization rate was statistically higher in those with peak serum
E2 levels below 1500 pg/ml, whereas among non-carriers of the AMHRII
(-482 A > G) polymorphism, number of follicles was higher in those with
more than two previous IVF attempts and total dose of gonadotropins was
lower in those with peak serum E2 levels above 1500 pg/ml.
There was evidence that in specific subgroups of women undergoing
IVF/ICSI, AMH and AMHRII SNPs may be related to patients’
characteristics and controlled ovarian stimulation and pregnancy outcome
and thus may provide a means for the prediction of ovarian response in
specific subgroups of women entering an IVF/ICSI program
Cleavage Stage versus Blastocyst Stage Embryo Transfer in Oocyte Donation Cycles
Background and Objective: During the last few years, a trend has been noted towards embryos being transferred at the blastocyst stage, which has been associated with improved rates regarding implantation and clinical pregnancy in comparison to cleavage stage embryo transfers. There is a limited number of studies investigating this notion in oocyte donation cycles employing cryopreserved embryos. The aim of this study is to evaluate the implantation potential and clinical pregnancy rates between the day 3 cleavage stage and blastocyst stage embryo transfers in oocyte donation cycles employing vitrified embryos. Methods: This is a retrospective evaluation of oocyte donation frozen–thawed transfers completed in our clinic from January 2017 to December 2017. Intracytoplasmic sperm injection was conducted for all oocytes. Following fertilization, all embryos were cryopreserved either at the cleavage or blastocyst stage. Embryo transfer of two embryos was performed under direct sonographic guidance in all cases. Results: Our results confirmed a 55.6% clinical pregnancy (CP) resulting from day 3 embryo transfers, a 68.8% CP from day 5, and 71.4% CP from day 6. Significantly improved pregnancy rates were related to embryo transfers at the blastocyst stage when compared to cleavage stage transfers (68.9% and 55.6% respectively, p = 0.016). The risk with regards to multiple pregnancies was similar. Conclusion: Our findings indicate that in oocyte donation cycles employing vitrified embryos, embryo transfer at the blastocyst stage is accompanied with a significant improvement in pregnancy rates and merits further investigation